Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells

Abstract Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate sy...

Full description

Bibliographic Details
Main Authors: Marwan Ibrahim Abdullah, Mohammed Najim Abed, Alan Richardson
Format: Article
Language:English
Published: Nature Publishing Group 2017-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-017-08649-9